Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-May-24 8:51 PM View:  | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Sale (Planned) | 32,507 | $74.69 | $2,427,950.00 | (16%) 207.36K to 174.85K | |
| 03-May-24 8:51 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Option Exercise | 34,249 | $4.86 | $166,285.00 | 17% 207.36K to 241.61K | |
| 03-May-24 8:51 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-May-24 | Planned Option Sale | 34,249 | $74.69 | $2,558,060.00 | (14%) 241.61K to 207.36K | |
| 02-May-24 9:27 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-May-24 | Option Exercise | 281,425 | $6.18 | $1,740,580.00 | 81% 348.51K to 629.93K | |
| 02-May-24 9:27 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-May-24 | Planned Option Sale | 281,425 | $78.66 | $22,136,500.00 | (45%) 629.93K to 348.51K | |
| 27-Mar-24 8:51 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 153,948 | $83.34 | $12,830,000.00 | (6%) 2.42M to 2.27M | |
| 27-Mar-24 8:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 31,667 | -- | -- | 9% 348.51K to 380.18K | |
| 27-Mar-24 8:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 16,610 | $83.34 | $1,384,280.00 | (7%) 223.97K to 207.36K | |
| 27-Mar-24 8:51 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 221,667 | -- | -- | 10% 2.2M to 2.42M | |
| 27-Mar-24 8:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Grant | 31,667 | -- | -- | 16% 192.3K to 223.97K | |
| 27-Mar-24 8:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 27-Mar-24 | Payment of Exercise | 16,610 | $83.34 | $1,384,280.00 | (4%) 380.18K to 363.56K | |
| 04-Mar-24 7:54 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 221,667 | -- | -- | 10% 2.14M to 2.36M | |
| 04-Mar-24 7:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 31,667 | -- | -- | 18% 180.73K to 212.4K | |
| 04-Mar-24 7:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 16,958 | $85.22 | $1,445,160.00 | (5%) 365.47K to 348.51K | |
| 04-Mar-24 7:54 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 162,815 | $85.22 | $13,875,100.00 | (7%) 2.36M to 2.2M | |
| 04-Mar-24 7:52 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Grant | 31,667 | -- | -- | 9% 333.8K to 365.47K | |
| 04-Mar-24 7:50 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 01-Mar-24 | Payment of Exercise | 20,093 | $85.22 | $1,712,330.00 | (9%) 212.4K to 192.3K | |
| 09-Feb-24 8:59 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 09-Feb-24 | Private Sale (Planned) | 45,000 | $29.90 | $1,345,500.00 | (2%) 2.18M to 2.14M | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Sale (Planned) | 80,000 | $26.87 | $2,149,790.00 | (4%) 2.26M to 2.18M | |
| 08-Feb-24 7:38 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Planned Option Sale | 25,000 | $28.05 | $701,250.00 | (100%) 25.0K to 0 | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Option Exercise | 189,079 | $3.76 | $711,367.00 | 8% 2.26M to 2.45M | |
| 08-Feb-24 7:40 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Planned Option Sale | 189,079 | $26.87 | $5,081,000.00 | (8%) 2.45M to 2.26M | |
| 08-Feb-24 7:38 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 08-Feb-24 | Option Exercise | 25,000 | $8.32 | $208,000.00 | 100% 0 to 25.0K | |
| 31-Jan-24 8:39 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 31-Jan-24 | Option Exercise | 85,000 | $1.23 | $104,550.00 | 4% 2.26M to 2.35M | |
| 31-Jan-24 8:39 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 31-Jan-24 | Planned Option Sale | 85,000 | $24.71 | $2,100,750.00 | (4%) 2.35M to 2.26M | |
| 30-Jan-24 9:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 30-Jan-24 | Planned Option Sale | 35,000 | $23.95 | $838,250.00 | (2%) 2.3M to 2.26M | |
| 30-Jan-24 9:05 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 30-Jan-24 | Option Exercise | 35,000 | $1.23 | $43,050.00 | 2% 2.26M to 2.3M | |
| 19-Jan-24 8:35 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 19-Jan-24 | Option Exercise | 30,000 | $8.32 | $249,600.00 | 100% 0 to 30.0K | |
| 19-Jan-24 8:35 PM View: | Rouan Sarah Kathryn Director | Viking Therapeutics, Inc. (VKTX) | 19-Jan-24 | Planned Option Sale | 30,000 | $23.05 | $691,500.00 | (100%) 30.0K to 0 | |
| 04-Jan-24 9:37 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 39,552 | $18.58 | $734,876.00 | (2%) 2.3M to 2.26M | |
| 04-Jan-24 9:36 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 14,199 | $18.58 | $263,817.00 | (4%) 348.0K to 333.8K | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Payment of Exercise | 13,872 | $18.58 | $257,742.00 | (7%) 209.6K to 195.73K | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 04-Jan-24 | Sale | 15,000 | $17.90 | $268,500.00 | (8%) 195.73K to 180.73K | |
| 04-Jan-24 9:37 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Payment of Exercise | 214,640 | $17.40 | $3,734,740.00 | (9%) 2.52M to 2.3M | |
| 04-Jan-24 9:36 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Payment of Exercise | 49,210 | $17.40 | $856,254.00 | (12%) 397.21K to 348.0K | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Payment of Exercise | 49,122 | $17.40 | $854,723.00 | (19%) 258.72K to 209.6K | |
| 04-Jan-24 9:37 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Grant | 310,000 | -- | -- | 14% 2.21M to 2.52M | |
| 04-Jan-24 9:36 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Grant | 98,334 | -- | -- | 33% 298.87K to 397.21K | |
| 04-Jan-24 9:35 PM View: | Zante Greg Chief Financial Officer | Viking Therapeutics, Inc. (VKTX) | 03-Jan-24 | Grant | 98,334 | -- | -- | 61% 160.39K to 258.72K | |
| 18-May-23 6:31 PM View: | Rowland Charles A Jr Director | Viking Therapeutics, Inc. (VKTX) | 16-May-23 | Planned Option Sale | 40,000 | $25.00 | $1,000,000.00 | (57%) 70.0K to 30.0K | |
| 18-May-23 6:30 PM View: | MacArtney Lawson Director | Viking Therapeutics, Inc. (VKTX) | 16-May-23 | Option Exercise | 16,000 | $1.19 | $19,040.00 | 33% 47.97K to 63.97K | |
| 18-May-23 6:31 PM View: | Rowland Charles A Jr Director | Viking Therapeutics, Inc. (VKTX) | 16-May-23 | Option Exercise | 40,000 | $1.08 | $43,200.00 | 133% 30.0K to 70.0K | |
| 18-May-23 6:30 PM View: | MacArtney Lawson Director | Viking Therapeutics, Inc. (VKTX) | 16-May-23 | Planned Option Sale | 16,000 | $24.00 | $384,000.00 | (25%) 63.97K to 47.97K | |
| 01-May-23 10:00 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 01-May-23 | Private Sale (Planned) | 45,000 | $22.45 | $1,010,250.00 | (2%) 2.24M to 2.2M | |
| 24-Apr-23 7:31 PM View: | MacArtney Lawson Director | Viking Therapeutics, Inc. (VKTX) | 24-Apr-23 | Planned Option Sale | 16,000 | $22.00 | $352,061.00 | (25%) 63.97K to 47.97K | |
| 24-Apr-23 7:31 PM View: | MacArtney Lawson Director | Viking Therapeutics, Inc. (VKTX) | 24-Apr-23 | Option Exercise | 16,000 | $3.33 | $53,280.00 | 33% 47.97K to 63.97K | |
| 21-Apr-23 7:29 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 19-Apr-23 | Private Sale (Planned) | 35,000 | $21.45 | $750,750.00 | (2%) 2.28M to 2.24M | |
| 18-Apr-23 7:08 PM View: | Mancini Marianna Chief Operating Officer | Viking Therapeutics, Inc. (VKTX) | 17-Apr-23 | Option Exercise | 12,500 | $13.07 | $163,375.00 | 4% 287.76K to 300.26K | |
| 18-Apr-23 7:10 PM View: | MacArtney Lawson Director | Viking Therapeutics, Inc. (VKTX) | 17-Apr-23 | Option Exercise | 20,786 | $8.00 | $166,288.00 | 43% 47.97K to 68.75K | |
| 18-Apr-23 7:09 PM View: | Lian Brian President & CEO Director | Viking Therapeutics, Inc. (VKTX) | 17-Apr-23 | Planned Option Sale | 125,000 | $20.45 | $2,556,260.00 | (5%) 2.43M to 2.31M |
